A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.

ABSTRACT:

Study question

Can increasing the duration of LH-exposure with a second dose of kisspeptin-54 improve oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS)?

Summary answer

A second dose of kisspeptin-54 at 10 h following the first improves oocyte yield in women at high risk of OHSS.

What is known already

Kisspeptin acts at the hypothalamus to stimulate the release of an endogenous pool of GnRH from the hypothalamus. We have previously reported that a single dose of kisspeptin-54 results in an LH-surge of ~12-14 h duration, which safely triggers oocyte maturation in women at high risk of OHSS.

Study design, size, duration

Phase-2 randomized placebo-controlled trial of 62 women at high risk of OHSS recruited between August 2015 and M

SUBMITTER: Abbara A 

PROVIDER: S-EPMC5850304 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature